Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Wingspan Stenting for Symptomatic Severe Stenosis of Intracranial Atherosclerosis Registry in China (WingspanSSIR)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2008 by Ministry of Health, China.
Recruitment status was:  Recruiting
Information provided by:
Ministry of Health, China Identifier:
First received: May 23, 2008
Last updated: May 27, 2008
Last verified: May 2008
This is a prospective, multi-center, non-randomized trial to study one-year outcomes of the Wingspan system for the treatment of Chinese patients with symptomatic atherosclerotic severe intracranial stenosis.

Condition Intervention
Intracranial Atherosclerosis
Procedure: Stenting of atherosclerotic intracranial stenosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Wingspan Stenting for Symptomatic Severe Stenosis of Intracranial Atherosclerosis Registry in China

Resource links provided by NLM:

Further study details as provided by Ministry of Health, China:

Primary Outcome Measures:
  • Any stroke or death within 30 days, plus ischemic stroke in the stented artery territory between 31 day and 1 year [ Time Frame: One year ]

Secondary Outcome Measures:
  • Ischemic stroke in the non-stented artery territory, hemorrhagic stroke and death from other vascular causes beyond 30 days, and emergent cerebral revascularization (ECER)and other major hemorrhages at any time within 1 year, and restenosis. [ Time Frame: One year ]

Estimated Enrollment: 200
Study Start Date: December 2007
Estimated Study Completion Date: October 2010
Estimated Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Stenting of atherosclerotic intracranial stenosis

    Patients will receive aspirin 300mg and clopidogrel 75mg per day for 3 days or more before stenting,and for at least 1 month after stenting. Modifiable risk factors will be controlled according to major international guidelines.

    All stenting procedures will be performed in an elective setting, and under local or general anesthesia. The study will be terminated if stroke or death rate within 30 days of the stenting exceeds 15%.

    Other Name: Wingspan stenting for intracranial stenosis
Detailed Description:

The study will enroll 200 Chinese patients with atherosclerotic intracranial stenosis of 70% to 99% that causes a recent ischemic neurologic event.

The Winspan stenting following undersized Gateway balloon angioplasty will be performed at experienced centers (at least 10 cases' experiences of using the Wingspan system to treat the patients with intracranial stenosis for each center).

The primary endpoint of the study, independently evaluated by neurologists, is any stroke or death within 30 days, plus ischemic stroke in the stented artery territory between 31 day and 1 year.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Chinese population with symptomatic severe stenosis of intracranial atherosclerosis

Inclusion Criteria:

  • An angiographically verified ≥ 70% stenosis of a major intracranial artery that causes TIA or minor stroke (NIH Stroke Scale score <9) within 90 days;
  • the lesion length <15 mm and normal arterial diameter adjacent to it between 2.0 mm and 4.5 mm;
  • patients having at least one atherosclerotic risk factor (arterial hypertension, diabetes mellitus, hyperlipidemia, hyperhomocysteinemia and cigarette smoking).

Exclusion Criteria:

  • Non-atherosclerotic stenosis;
  • intracranial hemorrhage in the territory of the stenotic artery within 6 weeks; potential source of cardiac embolism;
  • concurrent intracranial tumor, aneurysm and cerebral arteriovenous malformation;
  • tandem >50% stenosis of extracranial carotid or vertebral artery; known contraindication to heparin, aspirin, clopidogrel, anesthesia and contrast media; hemoglobin <10 g/dl, platelet count <100,000;
  • international normalized ratio >1.5 (irreversible) and uncorrectable bleeding diathesis; and life expectancy <1 years because of other medical conditions.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00685308

Contact: Wei-Jian Jiang, MD 86-10-6706-1935

Beijiang Tiantan Hospital, The Capital Medical University Recruiting
Beijing, China, 100050
Sponsors and Collaborators
Ministry of Health, China
Principal Investigator: Wei-Jian Jiang, MD Beijing Tiantan Hospital, The Capital Medical University, Beijing, China
  More Information

Responsible Party: Wei-Jian Jiang /Chairman of Interventional Neuroradiology, Beijing Tiantan Hospital, The Capital Medical University (CMU) Identifier: NCT00685308     History of Changes
Other Study ID Numbers: 1122837
Study First Received: May 23, 2008
Last Updated: May 27, 2008

Keywords provided by Ministry of Health, China:
Intracranial artery

Additional relevant MeSH terms:
Intracranial Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Intracranial Arterial Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases processed this record on May 22, 2017